Abivax (AAVXF) Cash & Equivalents (2021 - 2025)

Abivax has reported Cash & Equivalents over the past 5 years, most recently at $601.4 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $601.4 million for Q4 2025, up 290.26% from a year ago — trailing twelve months through Dec 2025 was $601.4 million (up 290.26% YoY), and the annual figure for FY2025 was $583.8 million, up 273.97%.
  • Cash & Equivalents for Q4 2025 was $601.4 million at Abivax, up from $154.1 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for AAVXF hit a ceiling of $601.4 million in Q4 2025 and a floor of $27.5 million in Q4 2022.
  • Median Cash & Equivalents over the past 5 years was $154.1 million (2024), compared with a mean of $224.7 million.
  • Biggest five-year swings in Cash & Equivalents: plummeted 60.4% in 2022 and later skyrocketed 885.88% in 2023.
  • Abivax's Cash & Equivalents stood at $69.4 million in 2021, then plummeted by 60.4% to $27.5 million in 2022, then skyrocketed by 885.88% to $271.1 million in 2023, then crashed by 43.15% to $154.1 million in 2024, then surged by 290.26% to $601.4 million in 2025.
  • The last three reported values for Cash & Equivalents were $601.4 million (Q4 2025), $154.1 million (Q4 2024), and $271.1 million (Q4 2023) per Business Quant data.